- Home
- AFJK vs IKNA Comparison
AFJK vs IKNA Comparison
Compare AFJK & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- IKNA
- Stock Information
- Founded
- AFJK 2023
- IKNA 2016
- Country
- AFJK United States
- IKNA United States
- Employees
- AFJK N/A
- IKNA N/A
- Industry
- AFJK
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- AFJK
- IKNA Health Care
- Exchange
- AFJK NYSE
- IKNA Nasdaq
- Market Cap
- AFJK 67.0M
- IKNA 61.8M
- IPO Year
- AFJK 2023
- IKNA 2021
- Fundamental
- Price
- AFJK $10.99
- IKNA $1.11
- Analyst Decision
- AFJK
- IKNA Buy
- Analyst Count
- AFJK 0
- IKNA 2
- Target Price
- AFJK N/A
- IKNA $3.00
- AVG Volume (30 Days)
- AFJK 4.1K
- IKNA 84.2K
- Earning Date
- AFJK 01-01-0001
- IKNA 05-12-2025
- Dividend Yield
- AFJK N/A
- IKNA N/A
- EPS Growth
- AFJK N/A
- IKNA N/A
- EPS
- AFJK 0.28
- IKNA N/A
- Revenue
- AFJK N/A
- IKNA N/A
- Revenue This Year
- AFJK N/A
- IKNA N/A
- Revenue Next Year
- AFJK N/A
- IKNA N/A
- P/E Ratio
- AFJK $38.87
- IKNA N/A
- Revenue Growth
- AFJK N/A
- IKNA N/A
- 52 Week Low
- AFJK $10.24
- IKNA $0.97
- 52 Week High
- AFJK $11.01
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- IKNA 38.47
- Support Level
- AFJK N/A
- IKNA $1.06
- Resistance Level
- AFJK N/A
- IKNA $1.25
- Average True Range (ATR)
- AFJK 0.00
- IKNA 0.10
- MACD
- AFJK 0.00
- IKNA 0.00
- Stochastic Oscillator
- AFJK 0.00
- IKNA 39.83
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.